The elderly constitute a sizeable proportion of the acute coronary syndrome (ACS) population, and this population is continually increasing in number.
INTRODUCTION
The elderly constitute a significant portion of the acute coronary syndrome (ACS) population, with over 75 year olds representing 27-34 % in European registries [1] . Furthermore, aging patients are an increasing cohort, with over 85 year olds expected to triple by the year 2035 [2] . This changing epidemiology presents new difficulties in diagnostic and management strategies. Cardiovascular medicine is a continually evolving and progressive discipline. However, elderly patients are frequently under-represented in clinical trials, leading to uncertainty among clinicians about the relative efficacy and safety of some treatments in this group and, as a consequence, they are less likely to receive evidence-based therapies [3] .
Although at higher baseline risk, this contributes further to the poorer outcomes in elderly patients compared with younger patient groups [4] . This paper aims to review and summarize the latest evidence and guidelines relevant to managing elderly patients, with discussion of current patterns of practice and the obstacles to delivering guideline-directed care.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
CLINICAL CHARACTERISTICS OF ELDERLY PATIENTS WITH ACS

Mehta et al. analyzed 163,140 hospital admissions of Medicare beneficiaries age C65
admitted from 1994 to 1996 and subcategorized these patients by age [5] . Increasing age was associated with a greater incidence of functional limitations, heart failure, prior coronary disease, and renal insufficiency [5] . Conversely, there is less diabetes and fewer male patients in older subgroups [5] . [6] . This showed increased hypertension, renal dysfunction, and previous PCI but reduced history of previous stroke, myocardial infarction, or heart failure compared to earlier cohorts [6] .
DIAGNOSIS AND INITIAL TREATMENT
Recognition of ACS can be difficult in older patient groups. This is due a combination of patient factors with multiple barriers to diagnosis, but also due to inadequacies in service provision. Elderly patient groups are less likely to call emergency services or make their own way to hospital, and patients aged over 65 who do contact emergency services were found to be given a lower priority than patients aged 51-64 years old [7, 8] guidelines state that the initial ECG should be taken within 10 min [9, 10] . However, the
CRUSADE (Can Rapid Risk Stratification of
Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines) registry highlighted that elderly patients ([85) on average wait an additional 7 min before receiving an initial ECG, and women over 85 were shown to wait for an average of 45 min [4, 11] .
Diagnosis is further delayed by the atypical presentation of elderly patients as found by the GRACE (Global Registry of Acute Coronary Events) registry [12] . Atypical symptoms included dyspnea in 49%, diaphoresis in 26 %, nausea or vomiting in 24%, and syncope in 19% ( Fig. 1 ) [12] . Other confounders to diagnosis found more frequently in these patients include Fig. 1 Elderly patients often present with atypical symptoms other than chest pain silent myocardial infarctions, which account for up to 60% of infarcts in patients over 85 years old, and concurrent illnesses such as pneumonia [4] .
Inequalities in care were also found on admission, with elderly patients less likely to be admitted to a cardiology ward or under the care of a consultant cardiologist [13] . This is likely multifactorial, due to factors such as delayed diagnosis, atypical presentation, increased resource requirements, and prolonged length of stay.
Given that elderly patients with ACS have poorer outcomes than their younger counterparts, in part due to the difficulties and delays in diagnosis, a high index of suspicion in the elderly population is therefore advised by European guidelines [10] .
ANTIPLATELETS
Antiplatelet agents as recommended for ACS by AHA/ACC and ESC guidelines are frequently underprescribed in the elderly [14] . Aspirin gained United States Food and Drug
Administration approval for use in primary and secondary prevention of cardiovascular disease in 1985. There are no trials designed to assess the effect of aspirin specifically in elderly patients, and elderly patients are underrepresented in other studies despite the increased risk of coronary heart disease and stroke in this group [15] . Analyses of previous trials have shown that patients over the age of 65 have a greater absolute risk reduction and a similar relative risk reduction in vascular end points than younger patient cohorts, and a 22% lower 30-day mortality (Fig. 2) [4, 14, 16] . Moreover, a similar trend of reduced risk of stroke, myocardial infarction (MI), vascular events, and death was witnessed in the very elderly ([85 years old) [14, 17] .
The GRACE registry demonstrated that age is independently linked to an increased bleeding risk in ACS patients. Although many studies have not shown increased bleeding in these groups with pharmacotherapy, this is likely due to patient selection, and concerns remain about bleeding in elderly groups [14, 17, 18] . This is further discussed in a review paper by Patrono et al., who highlight a marked increase in risk of bleeding complications in patients over the age of 70 and especially in patients with a history of gastrointestinal disturbance [15] . The review paper concludes that it is difficult to assess whether the possible benefits of aspirin exceed the risks of upper gastrointestinal bleeding in this age group [15] . However, current AHA/ACC and ESC guidelines recommend the initiation of aspirin in patients with suspected ACS without contraindications and regardless of their age [4, 9, 10] [20, 21] . Conversely, the combination of both drugs offers less benefits to elderly patients than in younger NSTE-ACS (non ST elevation myocardial infarction) patients with similar absolute (2.0% vs. 2.2%) and smaller relative (13.1% vs. 28.9%) risk reductions [4, 21, 22 ]. An exception is in elderly patients undergoing percutaneous coronary intervention (PCI) with higher risk scores or prior revascularization, where older patients had greater benefit [4, 23] . CURE showed an increase in the risk of major bleeding with dual therapy vs. aspirin alone (3.7% vs. 2.7% placebo; P = 0.001) and a small although nonsignificant 17% increase in the risk of life-threatening bleeding (2.1% vs. 1.8%, P = 0.13) [21] . Some authors suggest the routine use of proton pump inhibitors (PPI), which have been shown to decrease the higher incidence of gastrointestinal bleeding associated with antiplatelets in older patients [24] .
The recent introduction of more potent P2Y12 antiplatelet agents has raised more questions in treating the elderly with NSTE-ACS. Ticagrelor is increasingly used in the general population, but guidelines provide limited input with regards to prescription in elderly patients. PLATO (PLATelet inhibition and patient Outcomes) showed ticagrelor as compared with clopidogrel in patients with acute coronary syndromes (also receiving aspirin) was associated with significantly reduced rates of cardiovascular death, myocardial infarction, or stroke without an increase in overall major bleeding, although also with an increase in non-CABG-related bleeding (Fig. 3) Alcohol Concomitantly) score may help in such decision-making and acknowledges the increased bleeding risk with age [9] . Although some guidelines advocate the use of a narrower therapeutic range (2.0-2.5), this has not been investigated through prospective studies [9] .
OTHER THERAPIES
Adjunctive therapies are often underprescribed in the elderly, including patients with no clear contraindication. This is likely multifactorial, due to concerns about polypharmacy, drug interactions, and a lack of information on the risk benefit of medications in this population.
High [71] . Notably, the most powerful predictor of patient participation is physician referral and encouragement [72] . Patients who decline rehabilitation should be encouraged to exercise for at least 30 min on most days and preferably for 45 min 4-5 times a week [72] .
Several specific considerations must be made for elderly patients when considering cardiac rehabilitation. It is important to assess each individual's physical capability and consider the variations in physiology patients experience with age; for example, elderly patients could benefit from a longer warm-up time [73] . Moreover, an appropriate cooling-down period is particularly important to prevent hypotension (secondary to a delayed baroreceptor response post exercise) [73] .
REVASCULARIZATION
Due to a growing elderly population with a high prevalence of coronary disease, the question of whether to revascularize and the strategy of choice is becoming increasingly relevant. At present, research is limited regarding outcomes of elderly patients receiving revascularization therapies, as many major trials fail to enroll elderly subgroups [4, 61] .
The merits of revascularization have been shown in elderly patients with symptomatic stable ischemic heart disease. TIME (Trial of Invasive versus Medical therapy in Elderly patients with chronic symptomatic coronary artery disease) randomized 305 patients aged 75 and above with chronic angina (despite being treated with two antianginal medications) to revascularization vs. medical therapy only [74] . Patients in the revascularization group showed symptom relief and improved quality of life, with a reduction in the composite of death/MI/ readmission with ACS at 6 months (49% medical vs. 19% revascularization (P\0.0001) [70] . The large although observational APPROACH (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease) registry compared 4-year outcomes among 21,573 patients undergoing diagnostic cardiac catheterization. Those 70-79 years of age and, particularly, those C80 years of age showed greater adjusted reductions in death with revascularization compared with medical therapy than in those\70 years of age [75] . was one of the first to establish that patients presenting with non ST elevation ACS assigned to an early invasive strategy had a reduction in incidence of the composite of death, MI, or readmission with ACS compared with those treated by a conservative strategy [77] . Less well known is that the significant reduction in death or MI achieved with an invasive strategy was confined to those C65 years of age (8.8% vs.
13.6%; P = 0.018), and no significant difference was seen in those\65 years of age (6.1% vs. [79] . Patients with normal troponin levels on admission had no benefit from an early aggressive approach, but those with elevated troponin had a significant 57% reduction in the primary endpoint rate (P for interaction: 0.0375) [79] .
Choice of Revascularization Strategy
Factors such as morbidity, mortality, and complications should be considered when deciding upon the most appropriate revascularization strategy [9, 10] (predominantly on pump) was associated with higher in-hospital and 6-month mortality compared to PCI but improved survival from 6 months to 8 years [82] .
In a small observational study, Sheridan et al.
found that, even in the very elderly (aged 85 and over), while PCI was associated with improved early survival, CABG was associated with a small improvement in survival by 36 months (66% vs. 63%, P\0.05), although it was noted that the CABG patients were highly selected: they were without congestive heart failure, pulmonary disease, or peripheral vascular disease [83] . Appropriate patient selection for CABG is very important, particularly in the elderly. Alexander et al.
showed that 30-day mortality post-CABG was markedly higher in elderly patients overall (8.1% vs. 3% in younger patients), whereas elderly patients without significant comorbidity had a 30-day mortality of 4%-approaching that of their younger counterparts [84] .
In an analysis of ten trials, Hlatky et al. suggested that CABG confers a mortality benefit specifically in diabetic patients [65 years in comparison to PCI [85] . A systematic review of 66 studies (65 observational) concluded that revascularization could be performed in octogenarians with acceptable short-and long-term outcomes, but definite conclusions could not be drawn regarding survival benefit given the paucity of current data [85] .
Although these studies suggest that elderly patients free from comorbidity have postoperative outcomes approaching those of a younger age group, a more robust method of identifying these patients is required. This could allow a better understanding of the risks and benefits for both the patient and the medical team. Additionally, the risk of postoperative [94] . This trial showed a reduction in the primary endpoint (composite death from any cause or nonfatal Most evidence for ACS patients extrapolated from studies in younger age groups In the very elderly there is less evidence and one paper showed a possible association with harm in patients ≥80 years without CV disease [55] Consider use of lower intensity statin therapy in patients at increased risk of side effects e.g. the elderly-ESC [95] Not recommended in ≥75 year olds (or <60 kg or prior CVA/TIA) in both European and American guidelines [50, 95] If used a similar loading dose but a reduced maintenance dose of 5 mg should be considered [95] However elderly patients with a troponin rise had a 57% ↓ in primary endpoint (P for interaction= 0.0375) [79] Older patients with NSTE-ACS should be treated with GDMT, an early invasive strategy, and revascularization as appropriate.-AHA/ACC [9] Management decisions for older patients with NSTE-ACS should be patient centered, and consider patient preferences/goals, co morbidities, functional and cognitive status, and life expectancy.-AHA/ACC [9] Pharmacotherapy in older patients should be individualized and dose adjusted by weight and/or creatinine clearance to reduce adverse events caused by age-related changes in pharmacokinetics/dynamics, volume of distribution, co morbidities, drug interactions, and increased drug sensitivity. COMMIT early initiation ↑ risk of cardiogenic shock [69] Current Evidence, Risks and Benefits Guideline recurrent myocardial infarction in the first 30 days after randomization) with enoxaparin compared to unfractionated heparin in all subgroups [94] . The enoxaparin group experienced a higher rate of TIMI major bleeding (including intracranial hemorrhage) at 30 days [94] . This reduced dosing regimen is suggested by current ESC guidelines for patients [97] Pooled analysis with 2 prior trials showed an advantage of primary PCI over lysis in reducing death, re-infarction, or CVA at 30 days (OR, 0.64; 95% CI 0.45-0.91) [97] Current Evidence, Risks and Benefits Guideline ACS acute coronary syndrome, ACCF/AHA American College of Cardiology Foundation/American Heart Foundation, AHA/ACC American Heart Association/American Heart Association, AR absolute risk, ARB angiotensin receptor blocker, CABG coronary artery bypass graft, CAD coronary artery disease, CI confidence interval, CV cardiovascular, CVA cerebrovascular accident, ESC European Cardiac Society, GDMT guideline-directed medical therapy, HR hazard ratio, iv intravenous, kg kilograms, mg milligrams, LAD left anterior descending, MI myocardial infarction, NSTE-ACS non ST elevation acute coronary syndrome, OR odds ratio, P p value, PCI percutaneous coronary intervention, 
Current Evidence, Risks and Benefits Guideline
